MIDATECH PHARMA
Live / Registered — Registered (as of 09 Feb 2021)
What this means for you
Registered since 09 Feb 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79280356
- Registration number
- 6263411
- Mark type
- Design + words
- Filed
- 14 Nov 2019
- Published for opposition
- 24 Nov 2020
- Registered
- 09 Feb 2021
- Attorney of record
- Manuel Valcarcel
Goods and services
- Class 001 — Chemicals: Active chemical ingredients for use in the manufacture of pharmaceuticals, cosmetics and medicines for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders; nano-particle ingredients for use in pharmaceuticals, medicines and medicated cosmetics for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and medicines containing nano-particles for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders; vaccines incorporating nano-particles
- Class 040 — Treatment of materials: Custom manufacture of nano-particles for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders; custom manufacture of pharmaceuticals and medicines containing nano-particles; custom manufacture of nano-particle devices for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system and central nervous system related diseases and disorders
- Class 042 — Scientific and technological services: Scientific research services for others in the field of nano-particle technology; pharmaceutical and drug development and drug discovery services; scientific laboratory services, namely, testing, efficiency evaluation and advisory services in the field of nano-particles and nano-medicine; scientific laboratory services, namely, testing, efficiency and technical and scientific advisory services in the field of pharmaceuticals; scientific research laboratory services, namely, nano-particle laboratory services
Owner
- Midatech Limited, GB
- Midatech Limited, GB
- Midatech Limited, GB
Prosecution history
- 09 Feb 2026 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 07 Jun 2021 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 12 May 2021 — FINAL DISPOSITION NOTICE SENT TO IB
- 12 May 2021 — FINAL DISPOSITION PROCESSED
- 09 May 2021 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 09 Feb 2021 — REGISTERED-PRINCIPAL REGISTER
- 06 Dec 2020 — NOTIFICATION PROCESSED BY IB
- 24 Nov 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Nov 2020 — PUBLISHED FOR OPPOSITION
- 18 Nov 2020 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 18 Nov 2020 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 04 Nov 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Oct 2020 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Sept 2020 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 23 Sept 2020 — CORRESPONDENCE RECEIVED IN LAW OFFICE